Jagat Narula a, 1, Y. Chandrashekhar b, 1, Amir Ahmadi a, Suhny Abbara c, Daniel S.
Berman d, Ron Blankstein e, Jonathon Leipsic f, David Newby g, Edward D. Nicol h, Koen …

Ventricular assist device has rapidly emerged as a durable and safe therapy for end-stage
heart failure patients with> 22 000 implantations to date. Though originally conceived for …

This 30th adult heart transplant report is based on data submitted on 110,486 heart
transplants in recipients of all ages (including 99,008 adults) by 407 centers worldwide since …

Most patients with advanced systolic dysfunction who are assessed for a left ventricular
assist device (LVAD) also have some degree of right ventricular (RV) dysfunction. Hence …

Prezados colegas, Grandes avanços no diagnóstico, monitorização e tratamento da
Insuficiência Cardíaca (IC) foram observados nos últimos anos, com impactos reais na …

Rationale: Cell-based therapies are a promising intervention for the treatment of heart failure
(HF) secondary to ischemic and nonischemic cardiomyopathy. However, the clinical efficacy …

A major challenge in cardiac tissue engineering is the host's immune response to artificial
materials. To overcome this problem, we established a scaffold-free system for assembling …

The systemic right ventricle (SRV) is commonly encountered in congenital heart disease
representing a distinctly different model in terms of its anatomic spectrum, adaptation …

Background Heart transplantation is considered to be the gold standard treatment for
selected patients with end‐stage heart disease when medical therapy has been unable to …

Background: Ischemia–reperfusion injury (IRI) is one of the major risk factors implicated in
morbidity and mortality associated with cardiovascular disease. During cardiac ischemia, the …